Pharma industry challenges Canada’s drug pricing plan

Innovative Medicines Canada (IMC), an association that represents drugmakers in Canada, has challenged the overhaul of Canada’s drug-pricing regime.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Canada's drug pricing plan prompts backlash

26 October 2020 The final version of guidelines issued by Canada’s federal drug price regulator last week has caused uproar among the pharma industry.

Americas

Trump confounds big pharma with low-cost drugs import plan

1 August 2019 In a bid to lower drug prices for American patients, the Trump administration has proposed plans to allow the importation of cheaper drugs from Canada and other countries.

Big Pharma

Canadian generics plan could deter big pharma: report

17 April 2019 Plans by Canada’s government to improve access to generic drugs could deter pharmaceutical companies from releasing brand medicine in the country, according to an internal government report.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Pharma industry challenges Canada’s drug pricing plan

More on this story

Editor's picks

Editor's picks

More features